Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL529621 | 0.90 | HRH3 (0.51) | SIGMAR1SLC6A3HRH3TDP1L3MBTL1 | |
| SCHEMBL18474495 | 0.81 | L3MBTL1 (0.50) | SIGMAR1DRD2SLC6A4SLC6A3LTA4H | |
| SCHEMBL22236005 | 0.78 | ALDH1A1 (0.55) | HRH3HRH4TDP1 | |
| SCHEMBL3218005 | 0.75 | SIGMAR1 (0.75) | SIGMAR1DRD2SLC6A4SLC6A3LTA4H | |
| SCHEMBL15884438 | 0.75 | HRH3 (0.50) | LTA4HHRH3L3MBTL1 | |
| SCHEMBL3216167 | 0.74 | SIGMAR1 (0.73) | SIGMAR1DRD2SLC6A4SLC6A3LTA4H | |
| SCHEMBL3933570 | 0.73 | HRH4 (0.39) | SIGMAR1DRD2SLC6A4SLC6A3LTA4H | |
| Hydrochloric Acid SCHEMBL6965669 | 0.73 | SIGMAR1 (0.68) | SIGMAR1DRD2LTA4HHRH3L3MBTL1 | |
| SCHEMBL7452098 | 0.72 | CHRNB2 (0.65) | SIGMAR1DRD2SLC6A4SLC6A3LTA4H | |
| SCHEMBL22557523 | 0.72 | ALDH1A1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | claimed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | SIGMAR1 289/4885DRD2 2100/4885SLC6A4 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.